Humacyte
Humacyte reported revenue of $2 million in fiscal 2025. Its operating margin was −5,306.0%. Free cash flow was −$106 million. The diluted share count rose 33.5%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Humacyte does
Humacyte is a biotechnology company that grows replacement human blood vessels in its own facility. The vessels, which it calls acellular tissue engineered vessels, or ATEVs, are made from human cells that are then removed, so the company says they can be implanted in any patient without being rejected. Its first product, Symvess, won full FDA approval in December 2024 for adults with a serious artery injury in an arm or leg when the patient's own vein can't be used. It began selling Symvess in the United States in early 2025.
Symvess is its only approved product, so its sales are its main source of revenue. Humacyte is also testing the vessel in late-stage trials as a connection for patients on kidney dialysis, and plans to ask the FDA to approve that use. Further out, it is working on vessels for heart bypass surgery, for children's heart surgery and for treating Type 1 diabetes. It competes with surgeons using a patient's own veins and with synthetic grafts. A distribution deal gives Fresenius Medical Care the rights to sell its dialysis vessel outside the United States.
Humacyte makes its vessels at an 83,000 square foot plant in Durham, North Carolina, and had 184 employees at the end of 2025.
Its biggest risks, as it describes them
- Its dependence on Symvess, its only approved product, and on growing its sales to hospitals.
- Failing to win FDA approval for other uses, such as dialysis, after costly clinical trials.
- Doubt about its ability to keep operating, after years of losses and a need to raise more money.
- Its reliance on outside suppliers, some of them the only source of a part, and on Fresenius Medical Care.
- Hospitals, doctors and insurers may not accept or pay for Symvess and its future products.
Income statement
Humacyte lost money in fiscal 2025: a net loss of $41 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 226 | 152 | 80 | 45 | 50 |
| Debt incl. finance leases | 53 | 21 | 58 | 16 | 65 |
| Net debt (negative means net cash) | −172 | −131 | −23 | −28 | 14 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.4x | 0.2x | 4.2x | — | — |
| Interest coverage | −18.7x | −13.6x | −15.2x | −12.3x | −9.6x |
| Current ratio | 20.8x | 7.9x | 4.5x | 2.4x | 3.7x |
| Quick ratio | 20.8x | 7.9x | 4.5x | 2.4x | 3.0x |
Cash flow
Projections
Project Humacyte's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Humacyte says to expect
- Second half 2026: new hospitals added
Humacyte anticipates adding at least 20 new hospitals during the second half of 2026.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 3 insiders bought $89,990 of Humacyte shares on the open market, and 1 insider sold $41,298, all of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 14, 2026 | Keith Anthony JonesDirector | Bought | 10,000 | $0.56 | $5,600 | Form 4 |
| Aug 20, 2026 | Keith Anthony JonesDirector | Bought | 10,000 | $0.69 | $6,900 | Form 4 |
| Aug 17, 2026 | Keith Anthony JonesDirector | Bought | 30,000 | $0.59 | $17,700 | Form 4 |
| May 19, 2026 | Kathleen SebeliusDirector | Bought | 56,818 | $0.88 | $50,000 | Form 4 |
| May 18, 2026 | Dale A. SanderCFO and Chief Corp. Dev. Off | Sold plan | 45,887 | $0.90 | $41,298 | Form 4 |
| May 18, 2026 | Michael T. ConstantinoDirector | Bought | 11,000 | $0.89 | $9,790 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | 3 of 8 |
| Rule of 40 | — | — | — |
| Altman Z'' | −15.46 | −20.76 | −23.79 |
| Accruals ratio | −22.5% | −38.0% | 50.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Fail |
| Debt fell relative to assets | Fail | Pass | Fail |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | — | Pass |
| F-score | — | — | 3 of 8 |
Compare
Put Humacyte side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Humacyte | FY25 | — | −5,306.0% | −5,197.6% | — | — | 3 | |
| Aligos Therapeutics | FY25 | −39.5% | −4,024.9% | — | — | — | — | Compare |
| Celldex Therapeutics | FY25 | −78.0% | −18,599.8% | −13,829.1% | — | — | — | Compare |
| Absci | FY25 | −38.2% | −4,297.0% | −3,358.3% | −162.8% | — | 3 | Compare |
| Outlook Therapeutics | FY25 | — | −4,744.2% | — | — | — | — | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | — | — | — | 0 | 2 |
| Revenue growth | — | — | — | — | — | — |
| Gross profit | — | — | — | — | 0 | −8 |
| Research and development | 54 | 61 | 63 | 76 | 89 | 69 |
| Operating income | −65 | −81 | −85 | −100 | −114 | −108 |
| Net income | −66 | −26 | −12 | −111 | −149 | −41 |
| Diluted EPS (US$) | −11.54 | −0.66 | −0.12 | −1.07 | −1.26 | −0.26 |
| Diluted shares (millions) | 6 | 40 | 103 | 103 | 118 | 158 |
| Cash flow | ||||||
| Cash from operations | −56 | −81 | −71 | −73 | −98 | −105 |
| Capital expenditure | 0 | 0 | 1 | 2 | 2 | 1 |
| Free cash flow | −56 | −81 | −72 | −76 | −100 | −106 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 5 | 10 | 6 | 7 | 6 | 10 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 40 | 226 | 152 | 80 | 45 | 50 |
| Debt incl. finance leases | — | 53 | 21 | 58 | 16 | 65 |
| Total assets | 107 | 286 | 204 | 128 | 138 | 116 |
| Total liabilities | 36 | 164 | 87 | 115 | 190 | 113 |
| Shareholders' equity | −350 | 122 | 117 | 14 | −53 | 3 |
| Margins and ratios | ||||||
| Gross margin | — | — | — | — | — | −376.1% |
| Operating margin | — | — | — | — | — | −5,306.0% |
| Net margin | — | — | — | — | — | −2,003.6% |
| Free cash flow margin | — | — | — | — | — | −5,197.6% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | — |
| Return on capital | — | — | — | — | — | — |
| Return on equity | — | — | −10.0% | −169.8% | — | — |
| Return on assets | — | −13.5% | −4.9% | −66.6% | −111.8% | −32.1% |
| Net debt to EBITDA | — | — | — | — | — | — |